Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

CA 19-9 and CEA in Prognosis of Duodenal Adenocarcinoma: A Retrospective Study

News

April 18, 2023
PRESS RELEASE: On April 15, 2023, a new research paper was published in Oncotarget, entitled, “Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study.” continue reading »

Cancer Prevention With Rapamycin

News

April 17, 2023
PRESS RELEASE: On April 14, 2023, a new research perspective was published in Oncotarget, entitled, “Cancer prevention with rapamycin.” continue reading »

The Evolution of Metastatic Cancer: Mechanisms and Drivers

Oncotarget

April 14, 2023
In a new editorial, researchers explore genomic evolution in metastatic cancer, how therapy can drive it and the implications for developing new treatments.  continue reading »

Riluzole and Sorafenib in Patients With Advanced Solid Tumors: A Phase I Trial 

News

April 12, 2023
PRESS RELEASE: On April 10, 2023, a new research paper was published in Oncotarget, entitled, “A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.” continue reading »

Crosstalk Between Triple Negative Breast Cancer and Microenvironment

News

April 10, 2023
PRESS RELEASE: On March 31, 2023, researchers from Albany College published a new review in Oncotarget, entitled, “Crosstalk between triple negative breast cancer and microenvironment.” continue reading »